{"id":374468,"date":"2025-08-26T08:23:17","date_gmt":"2025-08-26T08:23:17","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/374468\/"},"modified":"2025-08-26T08:23:17","modified_gmt":"2025-08-26T08:23:17","slug":"three-billion-an-artificial-intelligence-ai-based-rare-genetic-disease-diagnostic-company-announ","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/374468\/","title":{"rendered":"Three Billion, an artificial intelligence (AI)-based rare genetic disease diagnostic company, announ.."},"content":{"rendered":"<p>YWHAG Genetic Variant Pediatric Genome Analysis provides a starting point for the design of customized treatments  <\/p>\n<p>            <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/08\/news-p.v1.20250826.77c173d5a53249d5ba75a1f15e375e9c_P1.jpg\" orgwidth=\"700\" orgheight=\"404\" alt=\"Images related to 3Billion's YWHAG gene mutation child genomic analysis support. Photograph = Three Billionaires\"\/>                      \uc0ac\uc9c4 \ud655\ub300                Images related to 3Billion&#8217;s YWHAG gene mutation child genomic analysis support. Photograph = Three Billionaires      <\/p>\n<p refid=\"2\">Three Billion, an artificial intelligence (AI)-based rare genetic disease diagnostic company, announced on the 26th that it will cooperate with the U.S. non-profit organization &#8220;N=1 Collaborative (N1C) to support precise dielectric analysis of children with ultra-rare YWHAG gene mutations.<\/p>\n<p refid=\"3\">The target of this support is James, a 5-year-old boy living in California, USA, who has a YWHAG mutation that causes seizures and developmental delays. There is no approved treatment for the ultra-rare disease, which has only about 50 reported cases worldwide, causing great difficulties for children and their families.<\/p>\n<p refid=\"4\">Three Billionaire used high-resolution WGS analysis and AI-based genetic mutation analysis technology to precisely analyze James&#8217; DNA. Key information that can target mutated genes was derived and provided to N1C, setting the starting point for customized treatment design.<\/p>\n<p refid=\"5\">N1C is the world&#8217;s first organization to receive US Food and Drug Administration (FDA) approval for a single patient-specific new drug &#8220;Milasen&#8221; in 2019, creating a global cooperative ecosystem that leads to the development of customized treatments for ultra-rare diseases.<\/p>\n<p refid=\"6\">Again, based on the results of the Three Billion analysis, we will promote the design of an ASO (Antisense Oligonucleotide) treatment for James with global clinical trial trustee (CRO) Charles River.<\/p>\n<p refid=\"7\">CEO Geum Chang-won said, &#8220;It is meaningful to join the support for James with N1C. We will continue to fulfill our social responsibility to open up new possibilities for patients with rare diseases with AI technology.&#8221;<\/p>\n","protected":false},"excerpt":{"rendered":"YWHAG Genetic Variant Pediatric Genome Analysis provides a starting point for the design of customized treatments \uc0ac\uc9c4 \ud655\ub300&hellip;\n","protected":false},"author":2,"featured_media":374469,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3846],"tags":[267,70,16,15],"class_list":{"0":"post-374468","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-genetics","8":"tag-genetics","9":"tag-science","10":"tag-uk","11":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/115094107185376647","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/374468","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=374468"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/374468\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/374469"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=374468"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=374468"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=374468"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}